Psoriatic Arthritis
📧 Sign up to get email alerts when something new happens for Psoriatic Arthritis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-12-17FDA Approved: YUSIMRY — Original Application (Coherus BioSciences Inc)
FDA approved YUSIMRY (adalimumab-aqvh) from Coherus BioSciences in an original biologics license application, likely as a biosimilar to adal…
-
FDA approval · 2021-12-14FDA Approved: XELJANZ XR — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for XELJANZ XR (tofacitinib) submitted by Pfizer Laboratories Div Pfizer Inc. The submission status …
-
FDA approval · 2021-12-14FDA Approved: XELJANZ — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for XELJANZ (tofacitinib) submitted by Pfizer Laboratories Div Pfizer Inc, resulting in updated …
-
FDA approval · 2021-12-02FDA Approved: XELJANZ XR — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for XELJANZ XR (tofacitinib) from Pfizer Laboratories Div Pfizer Inc. The approval authorizes the ex…
-
FDA approval · 2021-10-25FDA Approved: METHOTREXATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approves a supplemental application for Methotrexate by Hikma Pharmaceuticals USA Inc., enabling a new generic version of the drug.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2021-10-15FDA Approved: ADALIMUMAB-ADBM — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
FDA approves a supplemental application for the adalimumab biosimilar ADALIMUMAB-ADBM from Quallent Pharmaceuticals Health LLC. The approval…
-
FDA approval · 2021-06-17FDA Approved: INFLECTRA — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approves a supplemental application for INFLECTRA (infliximab-dyyb) from Pfizer Laboratories Div Pfizer Inc, marking FDA action on a bio…
-
FDA approval · 2021-06-14FDA Approved: TREXALL — Supplemental Application (Teva Women's Health, Inc.)
The FDA approved a supplemental application for TREXALL (methotrexate) filed by Teva Women's Health, Inc.
-
FDA approval · 2021-05-28FDA Approved: COSENTYX — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for COSENTYX (secukinumab) submitted by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2021-03-29FDA Approved: LEFLUNOMIDE — Original Application (Aurobindo Pharma Limited)
FDA approved an original-application generic for Leflunomide from Aurobindo Pharma Limited.
-
FDA approval · 2021-02-24FDA Approved: ADALIMUMAB — Supplemental Application (Sandoz Inc)
FDA approval of a supplemental application for the adalimumab biosimilar ADALIMUMAB-ADAZ from Sandoz Inc.
-
FDA approval · 2020-12-11FDA Approved: USTEKINUMAB — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for ustekinumab filed by Janssen Biotech, Inc. The action updates the product's labeling.
-
FDA approval · 2020-12-01FDA Approved: USTEKINUMAB — Supplemental Application (Janssen Biotech, Inc.)
FDA approves a supplemental application for ustekinumab (Stelara) from Janssen Biotech, Inc., reflecting an approval of changes to its label…
-
FDA approval · 2020-07-06FDA Approved: HULIO — Original Application (Biocon Biologics Inc)
FDA approved HULIO (adalimumab-fkjp) from Biocon Biologics Inc via an original Biologics License Application, a biosimilar to adalimumab. Th…
-
FDA approval · 2020-06-16FDA Approved: COSENTYX — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Cosentyx (secukinumab) submitted by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2020-05-29FDA Approved: TALTZ — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for TALTZ (ixekizumab) by Eli Lilly and Company. This action pertains to a supplemental filing under…
-
FDA approval · 2020-03-26FDA Approved: TALTZ — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for TALTZ (ixekizumab) from Eli Lilly and Company, indicating an updated or expanded indication …
-
FDA approval · 2020-02-04FDA Approved: LEFLUNOMIDE — Original Application (Lupin Pharmaceuticals, Inc.)
FDA approved the original application for Leflunomide from Lupin Pharmaceuticals, establishing a generic version of the drug.
-
FDA approval · 2019-12-12FDA Approved: XELJANZ XR — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for XELJANZ XR (tofacitinib) from Pfizer Laboratories Div Pfizer Inc, indicating an update to the pr…
-
FDA approval · 2019-12-06FDA Approved: AVSOLA — Original Application (Amgen, Inc)
FDA approved AVSOLA (infliximab-axxq) from Amgen as a biosimilar to infliximab, for the same indications as the reference product.
-
FDA approval · 2019-10-08FDA Approved: OLUMIANT — Supplemental Application (Eli Lilly and Company)
FDA approves Eli Lilly's supplemental application for OLUMIANT (baricitinib). This action updates the labeling to reflect expanded indicatio…
-
FDA approval · 2019-09-24FDA Approved: SIMPONI — Supplemental Application (Janssen Biotech, Inc.)
The FDA approved a supplemental application for SIMPONI (golimumab) submitted by Janssen Biotech, Inc. The approval updates the drug's label…
-
FDA approval · 2019-08-30FDA Approved: XELJANZ — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for XELJANZ (tofacitinib) submitted by Pfizer Laboratories Div Pfizer Inc, marking an approved modif…
-
FDA approval · 2019-07-25FDA Approved: XELJANZ — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA entry describing a supplemental application for XELJANZ (tofacitinib) submitted by Pfizer Laboratories Div Pfizer Inc.
-
FDA approval · 2019-07-25FDA Approved: XELJANZ XR — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for XELJANZ XR (tofacitinib extended-release), expanding its formulation under Pfizer's submission.